CardioMEMS is commercializing wireless MEMS-based pressure sensing technology for use inside of the human body.
Axion Biosystems is commercializing MEMS-based multielectrode array (MEA) technology, coupled with advanced signal processing circuitry, for in-vitro measurement of neural systems.
Redeon, acquired by Biovalve in 2001, was a microneedle company commercializing microfabrication-based approaches to transdermal drug delivery.
Both CardioMEMS and Redeon are graduates of the Advanced Technology Development Center (ATDC). Axion Biosystems is a current member of ATDC. Some economic development activities of our laboratory have been funded by the ATDC, the Georgia Research Alliance, and EmTech Bio.
For more information, please contact us.